We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery Plus Drugs for Advanced Pancreatic Cancer

By HospiMedica staff writers
Posted on 31 Oct 2003
Surgical resection combined with a four-drug chemotherapy regimen can triple the survival of patients with advanced pancreatic cancer, according to a study of 12 patients reported at the annual Clinical Congress of the American College of Surgeons in Chicago (IL, USA).

Patients in the study were thought to be candidates for surgery to remove their pancreatic tumors, but surgeons discovered the tumors were too extensive for the growths to be excised. More...
Instead, they treated the patients with chemotherapy to shrink the tumors to a resectable size. Patients received four different low-dose chemotherapy drugs until the pancreatic tumors in all but one patient were small enough to remove surgically. The median survival from the time of diagnosis was 35 months in those patients who had surgical resection. About 82% lived for two years, 41% lived for three years, and 27% lived for four years. Although seven of the 12 patients died of recurrent disease, five were still alive and disease free between 10 and 117 months after diagnosis.

"For patients who present with unresectable pancreatic cancer, the role of therapy has focused on the pancreas,” said William Isacoff, M.D., assistant clinical professor in the department of hematology and oncology at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center (USA). "But three months after they finish radiation, amny patients have liver metastases. Well, the liver metastases were already there, too small to see; so what the patients needed was effective systemic treatment.”





Related Links:
UCLA

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.